Appendix 1. Changes in the mean of Pediatric Sequential Organ Failure Assessment (PSOFA score), mean serum creatinine and mean of body temperature among critically ill pediatrics between two methods of vancomycin infusion based on the GEE method

Factors	Groups	Day 1	Day 2	Day 3	Day 4	Day 5	Last day of intervention	after	P_value	P_value	Comparison
								intervention cessation	time effect	time × groups	of time groups ¹
								COBBACION	CIICCI	groups	T1/T2*
PSOFA	CIV	8.30 ± 4.03	8.00 ± 3.90	7.06 ± 3.86	6.54 ± 3.83	6.60 ± 4.28	-	-	0.017*		T1/T3*
											T1/T4*
										<0.001*	T1/T5*
	IIV	6.62 ± 4.17	5.74 ± 3.77	4.88 ± 4.04	4.71 ± 4.06	4.76 ± 4.02	-	-	0.001*		T1/T3*
											T1/T4*
											T1/T5*
	Total	7.44 ± 4.16	6.83 ± 3.97	5.94 ± 4.07	5.57 ± 4.03	5.59 ± 4.21	-	-	<0.001*	-	T1/T2*
											T1/T3* T1/T4*
											T1/T5*
Serum creatinine (µmol/L)	CIV	0.52 ± 0.15	0.55± 0.15	0.53± 0.14	0.50± 0.17	0.49± 0.12	0.55± 0.17	0.51± 0.15	0.093		Non-
											significant
	IIV	0.54 ± 0.08	0.60± 0.65	0.47±0.08	0.49± 0.08	0.46±0.12	0.52 ± 0.18	0.55± 0.26	<0.001	<0.001*	T1/T3*
											T1/T4*
											T1/T5*
	Total	0.53 ± 0.12	0.57± 0.45	0.50± 0.12	0.49 ± 0.14	0.47 ± 0.12	0.53 ± 0.18	0.53 ± 0.21	0.005*	-	T1/T3*
											T1/T4*
Temperature (°C)											T1/T5* Non-
	CIV	37.53 ± 0.75	37.59 ± 0.94	37.40 ± 0.72	37.45 ± 0.65	37.38 ± 0.57	-	-	0.235	0.225	significant
	IIV	37.60 ± 0.77	37.63 ± 0.73	37.43 ± 0.59	37.41 ± 0.49	37.46 ± 0.58	-	-	0.208		Non-
											significant
	Total	37.57 ± 0.76	37.61 ± 0.84	37.42 ± 0.65	37.43 ± 0.57	37.42 ± 0.58	-	-	0.040*		Non-
										-	significant
37-1 11				l	l						6

Values described as mean \pm standard deviation,

CIV Continuous Infusions of Vancomycin, IIV Intermittent Infusions of Vancomycin

^{*} Statistically significant, $P_{value} < 0.05$ based on the linear Generalized Estimation Equation (GEE) method ¹ each visit time compared with visit time 1

Appendix 2. Results of the linear generalized estimating equation about the effect of intervention on mean changes of serum creatinine level, PSOFA and body temperature during the study

Factors	Groups	Model 1 Crude ß¹, 95% Cl	P_value	Model 2 Adjusted ß, 95% CI	P_value
um inine ɔl/L)	CIV	CIV Reference		Reference	-
Serum creatinine (µmol/L)	IIV	-0.002 (-0.05, 0.05)	0.933	0.01 (-0.04, 0.07)	0.603
FA	CIV Reference		-	Reference	-
PSOFA	IIV	-1.84 (-3.56, -0.13)	0.035*	-0.58 (-1.77, 0.59)	0.534
ature	CIV	Reference	-	Reference	-
Temperature (°C)	IIV	0.02 (-0.22, 0.28)	0.831	0.09 (-0.20, 0.37)	0.539

^{*}Statistically significant, P_value < 0.05

Model 1: Intercept groups

Model 2: Intercept gender, age, groups, inotrope drugs, total number of prescription drugs during hospitalization, PRISM score and length of hospital stay


CIV Continuous Infusions of Vancomycin, *IIV* Intermittent Infusions of Vancomycin, *PSOFA* Pediatric Sequential Organ Failure Assessment, *CI* Confidence Interval

¹Coefficient (ß)


Appendix 3. Initial model building to describe the population pharmacokinetic parameters of clearance (Cl) and volume of distribution (V), one compartmental structural model was the best model

Structural model	one compartment infusion	one compartment infusion	two compartment infusion
Individual model	V, Cl	V, Cl	Cl, V1, Q, V2
Used covariates	administration method	-	-
-2*LL (Lin)	873.34	895.94	916.64
BICc (Lin)	900.49	923.76	962.55


CIV Continuous Infusions of Vancomycin, IIV Intermittent Infusions of Vancomycin, -2*LL (Lin) -2*log-likelihood computed by linearization, BICc (Lin) corrected the Bayesian Information Criteria based on the log-likelihood computed by linearization




Appendix 4. Changes in the mean of Pediatric Sequential Organ Failure Assessment (PSOFA score) of critically ill pediatrics between two methods of vancomycin infusion during study time. *CIV* Continuous Infusions of Vancomycin, *IIV* Intermittent Infusions of Vancomycin



Appendix 5. Changes in mean of serum creatinine of critically ill pediatrics between two methods of vancomycin infusion during study time. *CIV* Continuous Infusions of Vancomycin, *IIV* Intermittent Infusions of Vancomycin



Appendix 6. Changes in mean body temperature of critically ill pediatrics between two methods of vancomycin infusion during study time. *CIV* Continuous Infusions of Vancomycin, *IIV* Intermittent Infusions of Vancomycin



Appendix 7. Predicted-corrected visual predictive check for vancomycin concentration versus time A) intermittent infusion of vancomycin method (IIV) B) continuous infusion of vancomycin method (CIV)